Compare Citius Pharmaceuticals Inc (CTXR) vs Rush Street Interactive Inc (RSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Rush Street Interactive Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Rush Street Interactive Inc trades at $33.5 (market cap $3.45B). The key difference: Rush Street Interactive Inc is far larger — about 235.7× Citius Pharmaceuticals Inc's market cap, and Rush Street Interactive Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | RSI | |
|---|---|---|
Market Cap | $14.64M | $3.45B |
Sector | Health | Technology |
52-Week High | $1.82 | $34.18 |
52-Week Low | $0.53 | $14.51 |
Enterprise Value | $10.86M | $3.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
RSI stock trades at $34.18, up 2.34% today, with a bullish technical signal from moving averages and strong institutional support. Recent Q1 2026 earnings beat expectations with EPS of $0.14 versus $0.12 expected, while revenue grew to $1.13B in 2025. The company expanded into Alberta with BetRivers launch, enhancing its online gaming footprint.
Outlook remains positive with 76.9% analyst buy ratings and a consensus price target of $29.44, though high valuation multiples (P/E 98.56) and overbought RSI levels near 77.56 pose near-term risks. Key catalysts include Q2 2026 earnings on July 29, 2026, and execution of the $100M share repurchase program.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →
